Market Overview

UPDATE: Wedbush Downgrades Illumina to Neutral on Risk/Reward

Share:
Related ILMN
There's Something Wrong With Illumina's Gene Sequencing Machine
What Would A $5.8 Billion NIH Cut Look Like? Devastation
The Vetr community has upgraded $ILMN to 4.5-Stars. (Vetr)

Wedbush reduced its rating on Illumina (NASDAQ: ILMN) from Outperform to Neutral and reiterated its $52 price target.

Wedbush noted, "We have spoken with several typical sequencing customers recently that are either putting off or second guessing HiSeq purchases because of the attractive price point of ILMN's own sequencing service. In addition, for the first time, we are hearing about instances of used HiSeq 2000's for sale on the secondary market at steep discounts. On a positive note, near-term project pipelines appear robust and, despite continued MiSeq teething pains, feedback remains largely positive to date, with plans for greater utilization by core labs in 2013."

Illumina closed at $55.55 on Thursday.

Latest Ratings for ILMN

DateFirmActionFromTo
Mar 2017Leerink SwannUpgradesMarket PerformOutperform
Feb 2017Evercore ISI GroupUpgradesHoldBuy
Jan 2017Deutsche BankInitiates Coverage OnHold

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (ILMN)

View Comments and Join the Discussion!